The alpha 1-adrenergic agonist methoxamine and the "loop" diuretic frusemide reduce nasal potential difference.
Pretreatment by inhalation with the alpha 1-adrenergic agonist methoxamine and the "loop" diuretic frusemide reduces the bronchial response to certain airway challenges in asthma. To test whether these drugs may act by altering airway epithelial ion and water transport, their effect on nasal potential difference (PD) when applied topically in eight normal volunteers was measured. For comparison, the effect of the Na(+)-channel blocking drug amiloride and the beta 2-adrenergic agonist salbutamol was also tested. Both methoxamine and frusemide significantly reduced PD: at the highest concentration given (10(-3) mol.l-1), there was a mean drop in PD from baseline of 39.5% following methoxamine treatment (p less than 0.05) and a mean drop of 30.2% following frusemide (p less than 0.05). Neither drug was as effective as amiloride, which caused a mean drop in PD of 27.5% from baseline at 10(-6) mol.l-1 and a drop of 71.6% at 10(-3) mol.l-1 (p less than 0.01 for each concentration). Salbutamol had no significant effect on PD (p greater than 0.05). We conclude that methoxamine and frusemide may derive their protective effect on some bronchial challenge, at least in part, from their effect on airway epithelial ion flux.
Wood
A M
AM
Dept of Respiratory Physiology, Papworth Hospital, Cambridge, UK.
Dinh Xuan
A T
AT
Cremona
G
G
Lockhart
A
A
Higenbottam
T W
TW
D000328:Adult; D000420:Albuterol / Q000494:pharmacology; D000584:Amiloride / Q000494:pharmacology; D005260:Female; D005665:Furosemide / Q000494:pharmacology*; D006801:Humans; D007474:Ion Exchange; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D008729:Methoxamine / Q000494:pharmacology*; D009297:Nasal Mucosa / Q000187:drug effects* / Q000502:physiology; D011199:Potentiometry
D000584:Amiloride; D005665:Furosemide; D008729:Methoxamine; D000420:Albuterol